Approval · Notice of Compliance 28520 · 2022
ACTONEL: Notice of Compliance 28520
Issued July 5, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28520
- Date
- July 5, 2022
- Company
- Allergan IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update the Product Monograph to the Health Canada Product Monograph 2020 Master template. Removal of the 5 mg and 30 mg discontinued strengths from the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACTONEL | Not yet assigned | — |
| ACTONEL DR | Not yet assigned | — |
Medicinal ingredients
- RISEDRONATE SODIUM HEMI-PENTAHYDRATE 35 MG per TAB
- RISEDRONATE SODIUM HEMI-PENTAHYDRATE 150 MG per TAB